These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19449763)

  • 1. [Insulin sensitizing drugs].
    Smahelová A
    Vnitr Lek; 2009 Apr; 55(4):425-8. PubMed ID: 19449763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 4. Future directions for insulin sensitizers in disease prevention.
    Colca JR
    Curr Opin Investig Drugs; 2007 Sep; 8(9):707-10. PubMed ID: 17729181
    [No Abstract]   [Full Text] [Related]  

  • 5. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli A; Formoso G
    Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational drug design and PPAR agonists.
    Perfetti R; D'Amico E
    Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.
    Beydoun H; Kancherla V; Stadtmauer L; Beydoun M
    Gynecol Endocrinol; 2013 Apr; 29(4):350-6. PubMed ID: 23323803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
    Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
    Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes mellitus: what is the optimal treatment regimen?
    Bell DS
    Am J Med; 2004 Mar; 116 Suppl 5A():23S-29S. PubMed ID: 15019860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR-gamma agonists and their role in type 2 diabetes mellitus management.
    Bermúdez V; Finol F; Parra N; Parra M; Pérez A; Peñaranda L; Vílchez D; Rojas J; Arráiz N; Velasco M
    Am J Ther; 2010; 17(3):274-83. PubMed ID: 20216208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.
    Hällsten K; Virtanen KA; Lönnqvist F; Janatuinen T; Turiceanu M; Rönnemaa T; Viikari J; Lehtimäki T; Knuuti J; Nuutila P
    Diabet Med; 2004 Dec; 21(12):1280-7. PubMed ID: 15569129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
    Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes, psoriasis and thiazolidinediones.
    Krentz AJ; Friedmann PS
    Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone.
    Kalra S; Gupta Y
    J Pak Med Assoc; 2015 Mar; 65(3):333-5. PubMed ID: 26554102
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
    Doshi LS; Brahma MK; Bahirat UA; Dixit AV; Nemmani KV
    Expert Opin Investig Drugs; 2010 Apr; 19(4):489-512. PubMed ID: 20367191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel insulin sensitizers: pharmacogenomic aspects.
    Otto C; Lehrke M; Göke B
    Pharmacogenomics; 2002 Jan; 3(1):99-116. PubMed ID: 11966407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.